June 2013 Newsletter

June 3, 2013:

2013 ARVO Meeting Spotlights Cutting-Edge Science in a New Venue

The conference embraced change as it focused on cutting-edge technology under the theme “Life-Changing Research.”

June 3, 2013:

Aspirin and AMD Revisited

Sunali Goyal, MD, weighed in on the ongoing controversy surrounding aspirin’s association with AMD during Monday’s session on translational research at ARVO.

June 3, 2013:

Valeant Pharmaceuticals to Acquire Bausch + Lomb for $8.7 Billion in Cash

Under the deal, Valeant will acquire Bausch + Lomb from the private equity firm Warburg Pincus LLC. Bausch + Lomb will keep its name and become a division of Valeant. 

June 3, 2013:

ReLACS: Gauging Surgeon Interest and Concerns

Few new technologies have garnered the amount of attention given to refractive laser-assisted cataract surgery.

June 3, 2013:

Increasing Adoption of ReLACS Will Lead to 11 Percent Growth Annually in Cataract Equipment Market

ReLACS used with USP continues to gain traction and is adding a new layer of revenue to the cataract equipment market while at the same time helping to expand the premium private-pay cataract surgery channel globally.

June 3, 2013:

AAO Challenges Senate Bill Requiring Patient-Specific Prescription Before Avastin Can Be Compounded

The legislation was passed out of committee on May 22 and now heads for the full Senate floor.

June 3, 2013:

June 2013 News Briefs

July 15, 2013:

Modest Growth Rate Forecast for the Single-Use Ophthalmic Surgical Device Market

Market Scope expects the market to generate $2.4 billion in sales in 2013, growing to $3.0 billion by 2018.

Social media